Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.
Wei L, Omata M, Lim YS, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-Oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han KH, Mizokami M, Duan Z. Wei L, et al. Among authors: doehle b. Antiviral Res. 2018 Oct;158:178-184. doi: 10.1016/j.antiviral.2018.08.001. Epub 2018 Aug 16. Antiviral Res. 2018. PMID: 30120954
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM, Ma J, Ding X, Afdhal NH, Kowdley KV, Gane EJ, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. Sarrazin C, et al. Gastroenterology. 2016 Sep;151(3):501-512.e1. doi: 10.1053/j.gastro.2016.06.002. Epub 2016 Jun 11. Gastroenterology. 2016. PMID: 27296509 Clinical Trial.
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
Mizokami M, Dvory-Sobol H, Izumi N, Nishiguchi S, Doehle B, Svarovskaia ES, De-Oertel S, Knox S, Brainard DM, Miller MD, Mo H, Sakamoto N, Takehara T, Omata M. Mizokami M, et al. Among authors: doehle b. J Viral Hepat. 2016 Oct;23(10):780-8. doi: 10.1111/jvh.12549. Epub 2016 May 15. J Viral Hepat. 2016. PMID: 27196675
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. Svarovskaia ES, et al. Among authors: doehle b. J Infect Dis. 2016 Apr 15;213(8):1240-7. doi: 10.1093/infdis/jiv564. Epub 2015 Nov 24. J Infect Dis. 2016. PMID: 26603202 Free PMC article.
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, Mo H, Chuang WL, Jacobson I, Dore GJ, Sulkowski M. Zeuzem S, et al. Among authors: doehle b. J Hepatol. 2017 May;66(5):910-918. doi: 10.1016/j.jhep.2017.01.007. Epub 2017 Jan 18. J Hepatol. 2017. PMID: 28108232 Free article.
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Hezode C, et al. Among authors: doehle bp. J Hepatol. 2018 May;68(5):895-903. doi: 10.1016/j.jhep.2017.11.032. Epub 2017 Dec 6. J Hepatol. 2018. PMID: 29221887 Clinical Trial.
44 results